David Deitchman - Concepedia

Author

David Deitchman

Bristol-Myers Squibb (United States)

Also Known As

D Deitchman, D. DEITCHMAN, D. Deitchman, David Deitchman

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Mead Johnson (United States)The University of Texas Southwestern Medical Center Montreal General Hospital University of Calgary

About

David Deitchman is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	2K
2	Natural Sciences	3	3	184
3	Biochemistry	3	3	184
4	Anesthesia	2	2	129
5	Health Sciences	1	1	19

David Deitchman

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement Michael R. Lassen, Bruce L. Davidson, Alexander Gallus, Journal of Thrombosis and Haemostasis Total Knee ReplacementThrombosisThrombopoiesisBlood PlateletMedicine	2007	370
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study Harry R. Büller, David Deitchman, Martin H. Prins, Journal of Thrombosis and Haemostasis ThrombosisVenous ThrombosisCardiovascular DiseaseBotticelli DvtPharmacology	2008	251
Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. John T. Flaherty, Bertram Pitt, J W Gruber, Circulation	1994	251
Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Eric J. Eichhorn, John B. Bedotto, Craig R. Malloy, Circulation Heart FailureCardiovascular DiseaseBeta-adrenergic BlockadeMedicinePhysiology	1990	243
Long-term β-Blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo E.M. Gilbert, J. G. Anderson, David Deitchman, The American Journal of Medicine Cardiac FunctionCardiomyopathyCardiovascular DiseasePharmacologyCardiovascular Pharmacology	1990	243
Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Susan Woodley, Edward M. Gilbert, Jeffrey L. Anderson, Circulation	1991	227
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer Mark N. Levine, Chu‐Shu Gu, Howard A. Liebman, Journal of Thrombosis and Haemostasis ThrombosisVenous ThrombosisOncologyPharmacologyClinical Trials	2012	190
Antihypertensive agents. Synthesis and biological properties of 2-amino-4-aryl-2-imidazolines W. L. Matier, D. Alfred Owens, William T. Comer, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceBioorganic ChemistryBiochemistry	1973	133
Clinical safety profile of sotalol in the treatment of arrhythmias Daniel J. MacNeil, Richard O. Davies, David Deitchman The American Journal of Cardiology Cardiac AnaesthesiaClinical Safety ProfileMedicinePharmacotherapyAnesthesia	1993	105
Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy Jeffrey L. Anderson, Edward M. Gilbert, John B. OʼConnell, Journal of the American College of Cardiology CardiomyopathyHeart FailureCardiovascular DiseaseBeta-adrenergic BlockadeMedicine	1991	80

Page 1